Trafalgar International (GCAN) Common Equity (2016 - 2026)
Trafalgar International (GCAN) posted Common Equity of -$775025.0 for Q1 2026, down 100.04% on a QoQ basis from $2.0 billion in Q4 2025, and up 5.94% year-over-year from -$731557.7 in Q1 2025.
Analysis
Trafalgar International (GCAN) Common Equity (2016 - 2026) Analysis & Trends
Trafalgar International has reported Common Equity for 11 years, with the latest figure at -$775025.0 in Q1 2026.
- On a quarterly basis, Common Equity rose 5.94% year-over-year to -$775025.0 in Q1 2026; TTM through Mar 2026 was -$775025.0, a 5.94% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 238117.88% from the prior year.
- Common Equity was -$775025.0 for Q1 2026 at Trafalgar International, down from $2.0 billion in the prior quarter.
- The five-year high for Common Equity was $2.0 billion in Q4 2025, with the low at -$1.1 million in Q3 2025.
- Average Common Equity over 5 years is $117.0 million, with a median of -$661232.0 recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Common Equity plunged 642.21% in 2022, then surged 238117.88% in 2025.
- Over 5 years, Common Equity stood at -$544830.0 in 2022, then decreased by 21.36% to -$661232.0 in 2023, then fell by 27.08% to -$840273.0 in 2024, then soared by 238117.88% to $2.0 billion in 2025, then slumped by 100.04% to -$775025.0 in 2026.
- The last three Common Equity figures came in at -$775025.0 (Q1 2026), $2.0 billion (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 80.86 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 2.61 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 6.34 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 6.40 Bn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | -775,025.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -775,025.00 |
| Dec 31, 2025 | 2.00 Bn |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | -823,984.00 |
| Dec 31, 2024 | -840,273.00 |
| Sep 30, 2024 | -796,925.00 |
| Jun 30, 2024 | -750,760.00 |
| Mar 31, 2024 | -705,843.00 |
| Dec 31, 2023 | -661,232.00 |
| Sep 30, 2023 | -650,371.00 |
| Jun 30, 2023 | -632,941.00 |
| Mar 31, 2023 | -587,898.00 |
| Dec 31, 2022 | -544,830.00 |
| Sep 30, 2022 | -561,429.00 |
| Jun 30, 2022 | -641,653.00 |
| Mar 31, 2022 | -616,748.00 |
| Dec 31, 2021 | -469,062.00 |
| Sep 30, 2021 | -272,731.00 |
| Jun 30, 2021 | -86,452.00 |